Photo of Professor Hayat  Onyuksel

Hayat Onyuksel

Professor of Pharmaceutics and Bioengineering, Biopharmaceutical Sciences
Faculty and Staff Committee, Diversity & Inclusion



833 South Wood Street; Room 358, Chicago, IL, 60612

Office Phone:

(312) 996-2097


Office Phone:

(312) 996-9277


Formulation and Drug Delivery
Development of novel targeted nanomedicines for cancer, and inflammatory diseases.

Selected Publications

  • Esparza K, Jayawardena D, Onyuksel H. Phospholipid Micelles for Peptide Drug Delivery. Ed. Weissig V. and Elbayoumi T. In Methods in Enzymology: Basic Protocols in Pharmaceutical Nanotechnology. 2018:
  • Bahadori F, Kocyigit A, Onyuksel H, Dag A, Topcu G. Cytotoxic, Apoptotic and Genotoxic Effects of Lipid-Based and Polymeric Nano Micelles, an In Vitro Evaluation.. Toxics. 2017;6(1). doi:10.3390/toxics6010007.
  • Jayawardena D, Anbazhagan AN, Guzman G, Dudeja PK, Onyuksel H. Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease.. Molecular pharmaceutics. 2017;14(11):3698-3708. doi:10.1021/acs.molpharmaceut.7b00452.
  • Jayawardena D, Guzman G, Gill RK, Alrefai WA, Onyuksel H, Dudeja PK. Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.. American journal of physiology. Gastrointestinal and liver physiology. 2017;313(1):G16-G25. doi:10.1152/ajpgi.00081.2017.
  • Anbazhagan AN, Thaqi M, Priyamvada S, Jayawardena D, Kumar A, Gujral T, Chatterjee I, Mugarza E, Saksena S, Onyuksel H, Dudeja PK. GLP-1 nanomedicine alleviates gut inflammation.. Nanomedicine : nanotechnology, biology, and medicine. 2017;13(2):659-665. doi:10.1016/j.nano.2016.08.004.
  • Yuan Z, Syed M, Panchal D, Joo M, Bedi C, Lim S, Onyuksel H, Rubinstein I, Colonna M, Sadikot RT. TREM-1-accentuated lung injury via miR-155 is inhibited by LP17 nanomedicine.. American journal of physiology. Lung cellular and molecular physiology. 2016;310(5):L426-38. doi:10.1152/ajplung.00195.2015.
  • Khaja F, Jayawardena D, Kuzmis A, Önyüksel H. Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis.. Nanomaterials (Basel, Switzerland). 2016;6(1). doi:10.3390/nano6010008.
  • Bahadori F, Topçu G, Eroğlu MS, Onyüksel H. A new lipid-based nano formulation of vinorelbine.. AAPS PharmSciTech. 2014;15(5):1138-48. doi:10.1208/s12249-014-0146-3.
  • Bahadori F, Dag A, Durmaz H, Cakir N, Onyuksel H, Tunca U, Topcu G, Hizal G. “Synthesis and characterization of biodegradable amphiphilic star and Y-shaped block copolymers as potential carriers for vinorelbine”. Polymers. 2014;6(1):214-242. doi:10.3390/polym6010214.
  • Vuković L, Madriaga A, Kuzmis A, Banerjee A, Tang A, Tao K, Shah N, Král P, Onyuksel H. Solubilization of therapeutic agents in micellar nanomedicines.. Langmuir : the ACS journal of surfaces and colloids. 2013;29(51):15747-54. doi:10.1021/la403264w.
  • Gülçür E, Thaqi M, Khaja F, Kuzmis A, Onyuksel H. Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells.. Drug delivery and translational research. 2013;3(6). doi:10.1007/s13346-013-0167-6.
  • Banerjee A, Onyuksel H. A novel peptide nanomedicine for treatment of pancreatogenic diabetes.. Nanomedicine : nanotechnology, biology, and medicine. 2013;9(6):722-8. doi:10.1016/j.nano.2012.12.005.
  • Sethi V, Rubinstein I, Kuzmis A, Kastrissios H, Artwohl J, Onyuksel H. Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.. Molecular pharmaceutics. 2013;10(2):728-38. doi:10.1021/mp300539f.
  • Dagar A, Kuzmis A, Rubinstein I, Sekosan M, Onyuksel H. VIP-targeted Cytotoxic Nanomedicine for Breast Cancer.. Drug delivery and translational research. 2012;2(6):454-62. doi:10.1007/s13346-012-0107-x.
  • Kuzmis A, Lim S, Desai E, Jeon E, Lee B, Rubinstein I, Onyuksel H. Micellar nanomedicine of human neuropeptide Y.. Nanomedicine : nanotechnology, biology, and medicine. 2011;7(4):464-71. doi:10.1016/j.nano.2011.01.004.